Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ADGM
ADGM logo

ADGM Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Adagio Medical Holdings Inc (ADGM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.680
1 Day change
-2.86%
52 Week Range
2.580
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Adagio Medical Holdings Inc (ADGM) is not a strong buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, lacks recent positive news catalysts, and has no immediate trading signals from Intellectia Proprietary Trading Signals. While analysts have a positive long-term outlook with a $3 price target, the current price trend and lack of financial data make it prudent to hold off on investing until more favorable conditions emerge.

Technical Analysis

The stock is showing bearish technical indicators. The MACD is above 0 but positively contracting, suggesting weakening momentum. The RSI is neutral at 24.932, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key support and resistance levels indicate the stock is trading near its support at S2: 0.664, with resistance at R1: 0.784.

Positive Catalysts

  • Analysts have initiated coverage with positive ratings and a $3 price target, citing innovative technology and a large market opportunity. Hedge funds are significantly increasing their positions, with a 1972.62% increase in buying activity over the last quarter.

Neutral/Negative Catalysts

  • The stock has shown a regular market decline of -2.86% and a post-market decline of -1.03%. There is no recent news or event-driven catalyst to support upward momentum. Technical indicators are bearish, and there is no recent congress trading data.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts from Lucid Capital and Piper Sandler have initiated coverage with Buy and Overweight ratings, respectively, and a $3 price target. They highlight the company's innovative cryoablation technology and its potential to capture a significant share of a $1.6B domestic market opportunity.

Wall Street analysts forecast ADGM stock price to rise
1 Analyst Rating
Wall Street analysts forecast ADGM stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.700
sliders
Low
4
Averages
4
High
4
Current: 0.700
sliders
Low
4
Averages
4
High
4
Lucid Capital
Buy
initiated
$3
AI Analysis
2026-06-03
Reason
Lucid Capital
Price Target
$3
AI Analysis
2026-06-03
initiated
Buy
Reason
Lucid Capital initiated coverage of Adagio Medical with a Buy rating and $3 price target. The company created an ablation catheter that is purpose built for ventricular tachycardia, the analyst tells investors in a research note. The firm believes the \"stage is set\" for atrial fibrillation-like market acceleration off a base growing 5%-8% today, with Adagio \"as the clear victor.\"
Piper Sandler
Matt O'Brien
Overweight
initiated
$3
2026-04-14
Reason
Piper Sandler
Matt O'Brien
Price Target
$3
2026-04-14
initiated
Overweight
Reason
Piper Sandler analyst Matt O'Brien initiated coverage of Adagio Medical with an Overweight rating and $3 price target. The firm says the company has developed a novel ultra-low temperature cryoablation technology for the treatment of ventricular tachycardia. Piper expects the pivotal results from the FULCRUM-VT trial should support FDA approval and commercial launch in 2027. The "large, underpenetrated" $1.6B domestic opportunity provides "ample opportunity" for sales growth potential and could deliver upside to expectations, contends Piper.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ADGM
Unlock Now

People Also Watch